PHILADELPHIA and KFAR SABA, Israel, Aug. 10, 2015 /PRNewswire/ -- ControlRad Systems Inc., a medical device company developing innovative products that dramatically reduce damaging radiation exposure to patients and physicians during fluoroscopic procedures, announced today that a fourth patent (U.S. Patent Number 9,095,283) was granted from the U.S. Patent and Trademark Office. The company continues to build its extensive portfolio and has an additional nine patents filed.
"We are thrilled at yet another issued patent further demonstrating our innovative approach," said Guillaume Bailliard, Chief Executive Officer. "Long-term ionizing radiation exposure is increasingly being recognized as a threat to physicians performing fluoroscopy procedures and ControlRad Systems patented products can play a critical role in mitigating the threat."
About ControlRad Systems
ControlRad Systems (CRS) is a medical device company developing innovative products that have the potential to dramatically reduce the risks of procedure related radiation exposure for patients, physicians, and all healthcare providers associated with fluoroscopic procedures, while maintaining if not improving image quality and workflow. This is accomplished with a propriety technology that optimizes the radiation dose to the clinically relevant region of interest while still providing important peripheral vision detail using state-of-the-art eye tracking technology to adjust in real-time high speed dynamic filters. ControlRad Systems is headquartered in greater Philadelphia and has engineering development facilities in Kfar Saba, Israel. To learn more, visit www.controlradsystems.com.
Contact: Guillaume Bailliard
SOURCE ControlRad Systems